247 related articles for article (PubMed ID: 27440861)
1. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Nguyen HQ; Callegari E; Obach RS
Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
Nguyen HQ; Kimoto E; Callegari E; Obach RS
Drug Metab Dispos; 2016 May; 44(5):781-91. PubMed ID: 26956641
[TBL] [Abstract][Full Text] [Related]
3. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
[TBL] [Abstract][Full Text] [Related]
4. Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice.
Shen HW; Yu AM
Drug Metab Lett; 2009 Dec; 3(4):234-41. PubMed ID: 19995332
[TBL] [Abstract][Full Text] [Related]
5. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
Nguyen HQ; Lin J; Kimoto E; Callegari E; Tse S; Obach RS
J Pharm Sci; 2017 Sep; 106(9):2758-2770. PubMed ID: 28412400
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
8. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
Ereshefsky L; Riesenman C; Lam YW
Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling to Evaluate the Systemic Exposure of Gefitinib in CYP2D6 Ultrarapid Metabolizers and Extensive Metabolizers.
Chen Y; Zhou D; Tang W; Zhou W; Al-Huniti N; Masson E
J Clin Pharmacol; 2018 Apr; 58(4):485-493. PubMed ID: 29193123
[TBL] [Abstract][Full Text] [Related]
11. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
12. Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers.
Ullmann U; Lehnfeld R; Bliesath H; Birkel M; Gebbing H; Gräve M; Wolf H
Int J Clin Pharmacol Ther; 2001 Jun; 39(6):271-6. PubMed ID: 11430636
[TBL] [Abstract][Full Text] [Related]
13. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients.
Schenk PW; van Fessem MA; Verploegh-Van Rij S; Mathot RA; van Gelder T; Vulto AG; van Vliet M; Lindemans J; Bruijn JA; van Schaik RH
Mol Psychiatry; 2008 Jun; 13(6):597-605. PubMed ID: 17667959
[TBL] [Abstract][Full Text] [Related]
14. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
15. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
[TBL] [Abstract][Full Text] [Related]
16. Effect of venlafaxine on imipramine metabolism.
Albers LJ; Reist C; Vu RL; Fujimoto K; Ozdemir V; Helmeste D; Poland R; Tang SW
Psychiatry Res; 2000 Nov; 96(3):235-43. PubMed ID: 11084219
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers.
Marasanapalle VP; Masimirembwa C; Sivasubramanian R; Sayyed S; Weinzierl-Hinum A; Mehta D; Kapungu NN; Kanji C; Thelingwani R; Zack J
J Clin Pharmacol; 2024 May; 64(5):578-589. PubMed ID: 37803948
[TBL] [Abstract][Full Text] [Related]
18. Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl] ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs.
Yamamoto T; Hagima N; Nakamura M; Kohno Y; Nagata K; Yamazoe Y
Xenobiotica; 2004 Jul; 34(7):687-703. PubMed ID: 15672756
[TBL] [Abstract][Full Text] [Related]
19. Imipramine: a model drug for P450 research.
Brøsen K; Skjelbo E; Nielsen KK
Methods Enzymol; 1996; 272():177-86. PubMed ID: 8791776
[No Abstract] [Full Text] [Related]
20. Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
Gueorguieva I; Jackson K; Wrighton SA; Sinha VP; Chien JY
Br J Clin Pharmacol; 2010 Oct; 70(4):523-36. PubMed ID: 20840444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
